Werewolf Therapeutics, Inc. (HOWL)

Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics engineered to stimulate the body's immune system to treat cancer. It uses its proprietary PREDATOR protein engineering platform to design conditionally activated molecules, called INDUKINE molecules, that stimulate both adaptive and innate immunity. These molecules are meant to stay inactive in peripheral tissue and activate selectively in the tumor microenvironment (TME), with the aim of overcoming the toxicity and poor pharmaceutical properties of conventional proinflammatory cytokine therapies. The company has worldwide rights to the platform and its portfolio of INDUKINE candidates, all developed internally, and is also expanding the platform toward other areas such as inflammatory diseases.

Each lead INDUKINE molecule combines four components: a wild-type cytokine, an inactivation domain that blocks the cytokine outside the tumor, a half-life extension domain, and a proprietary protease-cleavable linker. The linker is cleaved in the TME to release the active cytokine. Linkers are chosen by screening a proprietary peptide library against primary human tumor specimens and normal tissues. The pipeline has four initial candidates. WTX-124 is a conditionally activated IL-2 INDUKINE and the lead candidate, in a Phase 1/1b trial in advanced or metastatic solid tumors as monotherapy and with pembrolizumab, initially targeting melanoma, renal cell carcinoma and non-small cell lung cancer. WTX-330 is a conditionally activated IL-12 INDUKINE in a Phase 1 trial in advanced or metastatic solid tumors or lymphoma resistant to, or ineligible for, checkpoint inhibitors. JZP898 (formerly WTX-613), a conditionally activated interferon alpha INDUKINE, is being developed and commercialized by Jazz Pharmaceuticals Ireland Limited under a collaboration. WTX-712, a conditionally activated IL-21 INDUKINE, was recently nominated as the next development candidate and is in preclinical development. The company is also pursuing additional immuno-oncology discovery programs.

The company targets patients with advanced or metastatic solid tumors and lymphoma, including those who are unresponsive to or ineligible for immune checkpoint inhibitors, a population it sees as underserved. Its markets are immuno-oncology and cytokine therapy, where approved cytokines such as aldesleukin and interferon-alfa2b are limited by toxicity and short half-life. The strategy includes advancing WTX-124, WTX-330 and WTX-712, continuing the Jazz collaboration, and selectively entering strategic partnerships while retaining key rights in major pharmaceutical markets.

The company seeks patent protection in the United States and internationally. Its PREDATOR platform patent portfolio currently consists of two recently filed families of pending applications covering protease-cleavable linkers, linker libraries, and methods of making and screening them. No patents have yet been granted. The text does not describe its suppliers, manufacturing, or headquarters.